Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

828
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
828
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.0K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.0K
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

2.0K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.0K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Oncogenic <i>PIK3CA</i> mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.

Journal for immunotherapy of cancer·2026
Same author

Association between preoperative serum albumin and long-term all-cause mortality after percutaneous vertebroplasty for vertebral compression fracture.

PloS one·2026
Same author

Validation of ICD-10-CM diagnosis codes for identifying COVID-19 cases using administrative claims data in Taiwan.

BMC infectious diseases·2026
Same author

Effectiveness and Safety of Bempedoic Acid in Taiwanese Patients With Hypercholesterolemia: A Pragmatic Phase 4 Study (CLEAR Taiwan Study).

Journal of the American Heart Association·2026
Same author

Prognostic value of peak tricuspid regurgitation velocity in hospitalized patients with heart failure with preserved ejection fraction: an multi-institutional study.

Annals of medicine·2026
Same author

Paraspinal muscle fatty infiltration is associated with nonunion and cage subsidence after anterolateral lumbar interbody fusion: a level-specific analysis.

Scientific reports·2026

相关实验视频

Updated: Sep 10, 2025

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.4K

胆酶抑制剂与心力衰竭的较低死亡率相关:多中心倾向评分研究

Ming-Jer Hsieh1, Cheng-Hung Lee2, Dong-Yi Chen2

  • 1Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan; Heart failure center, Chang Gung Memorial Hospital, Linkou, Taiwan.

The Canadian journal of cardiology
|August 21, 2025
PubMed
概括
此摘要是机器生成的。

胆酶抑制剂显著降低了心力衰竭患者的死亡率和心力衰竭患者的住院治疗 (HFpEF). 这表明ChEIs可能是HFpEF的可行治疗方法.

关键词:
胆酶抑制剂心力衰竭保存的喷射分数长期死亡率副交感性

更多相关视频

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

相关实验视频

Last Updated: Sep 10, 2025

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.4K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

科学领域:

  • 心脏病学
  • 药理学
  • 医学研究

背景情况:

  • 通过阴道调节的副交感途径是心力衰竭 (HF) 的未充分研究的治疗策略.
  • 胆酶抑制剂 (ChEIs) 增强胆基调,并且在HF患者中显示出治疗效益.
  • 本研究检查了CHEI使用对诊断为心力衰竭与保存喷射分数 (HFpEF) 的患者的临床结果的影响.

研究的目的:

  • 研究使用胆酶抑制剂 (ChEIs) 与心力衰竭患者 (HFpEF) 的临床结果之间的关联.

主要方法:

  • 一项回顾性队列研究利用了2002年7月至2022年12月的多机构数据库.
  • HFpEF被定义为左心室喷射分数> 50% 和H2FPEF得分≥6.
  • 首要终点包括全因和心血管死亡率,以及在5年的随访期内住院治疗HF.

主要成果:

  • 使用CHEI与显著降低全因死亡率 (HR 0.45) 和心血管死亡率 (HR 0.41) 有关.
  • 与非使用者相比,使用ChEIs的患者心力衰竭住院的次数较少 (HR0. 52).
  • 对于使用CHEI的患者,左心室填充压的发生率较低 (E/ e≥13) (43. 4%对65. 1%,p=0. 010).

结论:

  • 在HFpEF中,胆酶抑制剂治疗与死亡率和HF住院率的显著降低有关.
  • 在ChEI使用者中观察到左心室填充压力的改善.
  • 这些发现需要进行进一步的前性试验,以评估CHEIs作为HFpEF的潜在治疗选择.